Clinical trials: Recurrent Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer, Malignant Tumor of Peritoneum
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This phase I/II trial is studying the side effects and best dose of VEGF Trap when given together with docetaxel and to see how well they work in treating patients with persistent or recurrent ovarian epithelial cancer, primary…
- Conditions
- Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00436501
- Testing
- docetaxel, ziv-aflibercept, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
This phase I trial is studying the side effects and best dose of decitabine when given together with pegylated liposomal doxorubicin hydrochloride and vaccine therapy in treating patients with recurrent ovarian epithelial cancer…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01673217
- Testing
- decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00303888
- Testing
- docetaxel, idronoxil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Yale University
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT02446600
- Testing
- Biospecimen Collection, Carboplatin, Cediranib Maleate
- Where
- 356 sites in United States, Canada and 2 more
- Volunteers
- 579 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005025
- Testing
- herpes simplex thymidine kinase, ganciclovir
- Where
- United States
- Sponsor
- John Stoddard Cancer Center at Iowa Methodist Medical Center
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
This phase I/II trial studies the side effects and best dose of olaparib when give together with durvalumab and tremelimumab and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal…
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02953457
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00006267
- Testing
- rubitecan
- Sponsor
- Gynecologic Oncology Group
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03552471
- Testing
- Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer, Fallopian Tube
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination.
- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
- Trial name
- NCT02737787
- Testing
- WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
The main purpose of this study is to begin to collect information and try to learn whether or not the combination of oxaliplatin, gemcitabine and bevacizumab works in treating women with recurrent mullerian carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00418093
- Testing
- Gemcitabine, Oxaliplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Fallopian Tube Cancer
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/II randomized study for subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-L, an autologous vaccine comprised of…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01312389
- Testing
- OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
This is a multicenter, open-label, non-randomized pilot study (Phase II). The aim is to obtain evidence of efficacy of niraparib and dostarlimab (TSR-042) in patients with relapsed ovarian cancer in two experimental cohorts and…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05126342
- Testing
- Niraparib, Dostarlimab
- Sponsor
- AGO Research GmbH
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003670
- Testing
- arzoxifene hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Eli Lilly and Company
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal…
- Conditions
- FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01970722
- Testing
- Carboplatin, Cisplatin, Gemcitabine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
In April 2017, Tesaro, Inc. opened an expanded access program (EAP) to make niraparib, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor, available to eligible women with recurrent epithelial ovarian, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04546373
- Testing
- Niraparib
- Where
- 57 sites in Spain
- Volunteers
- 316 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm
- Trial name
- NCT02111941
- Testing
- Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies the side effects of paclitaxel and bevacizumab with or without emactuzumab and how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has…
- Conditions
- Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT02923739
- Testing
- Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Primary Peritoneal Cavity Cancer
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- COCHISE (NCT00766142)
- Testing
- cetuximab, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Bergonié